{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:10:07Z","timestamp":1791987007208,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"512 Talent Cultivation Plan of Bengbu Medical College","award":["51201315"],"award-info":[{"award-number":["51201315"]}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"crossref","award":["2008085QH401"],"award-info":[{"award-number":["2008085QH401"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12026-022-09329-1","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T06:10:41Z","timestamp":1666937441000},"page":"60-69","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The association of IL-33 and systemic sclerosis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"71","author":[{"given":"Wanrong","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-2910","authenticated-orcid":false,"given":"Zhaohui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"issue":"6","key":"9329_CR1","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.autrev.2021.102831","volume":"20","author":"C-H Escobar-Soto","year":"2021","unstructured":"Escobar-Soto C-H, Mejia-Romero R, Aguilera N, Alzate-Granados JP, Mendoza-Pinto C, Mungu\u00eda-Realpozo P. Human mesenchymal stem cells for the management of systemic sclerosis Systematic Review. Autoimmun Rev. 2021;20(6):102831. https:\/\/doi.org\/10.1016\/j.autrev.2021.102831.","journal-title":"Autoimmun Rev"},{"issue":"10103","key":"9329_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9.","journal-title":"Lancet"},{"issue":"7","key":"9329_CR3","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","volume":"60","author":"M Bairkdar","year":"2021","unstructured":"Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema EV, Holmqvist M. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(7):3121\u201333. https:\/\/doi.org\/10.1093\/rheumatology\/keab190.","journal-title":"Rheumatology (Oxford)"},{"key":"9329_CR4","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fimmu.2019.02025","volume":"10","author":"D Xu","year":"2019","unstructured":"Xu D, Mu R, Wei X. The roles of IL-1 family cytokines in the pathogenesis of systemic sclerosis. Front Immunol. 2019;10:2025. https:\/\/doi.org\/10.3389\/fimmu.2019.02025.","journal-title":"Front Immunol"},{"key":"9329_CR5","doi-asserted-by":"publisher","unstructured":"Murdaca G, Greco M, Tonacci A, Negrini S, Borro M, Puppo F. IL-33\/IL-31 axis in immune-mediated and allergic diseases. Int J Mol Sci (2019): 20(23). https:\/\/doi.org\/10.3390\/ijms20235856.","DOI":"10.3390\/ijms20235856"},{"key":"9329_CR6","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.3389\/fimmu.2018.02663","volume":"9","author":"L Li","year":"2018","unstructured":"Li L, Zhu H, Zuo X. Interleukin-33 in systemic sclerosis: expression and pathogenesis. Front Immunol. 2018;9:2663. https:\/\/doi.org\/10.3389\/fimmu.2018.02663.","journal-title":"Front Immunol"},{"issue":"6","key":"9329_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","volume":"34","author":"S Vettori","year":"2014","unstructured":"Vettori S, Cuomo G, Iudici M, D\u2019Abrosca V, Giacco V, Barra G. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol. 2014;34(6):663\u20138. https:\/\/doi.org\/10.1007\/s10875-014-0037-0.","journal-title":"J Clin Immunol"},{"issue":"2","key":"9329_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00393-016-0202-3","volume":"77","author":"YJ Zhang","year":"2018","unstructured":"Zhang YJ, Zhang Q, Yang GJ, Tao JH, Wu GC, Huang XL. Elevated serum levels of interleukin-1\u03b2 and interleukin-33 in patients with systemic sclerosis in Chinese population. Z Rheumatol. 2018;77(2):151\u20139. https:\/\/doi.org\/10.1007\/s00393-016-0202-3.","journal-title":"Z Rheumatol"},{"key":"9329_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.imlet.2017.11.012","volume":"195","author":"CM Artlett","year":"2018","unstructured":"Artlett CM. The IL-1 family of cytokines. Do they have a role in scleroderma fibrosis? Immunol Lett. 2018;195:30\u20137. https:\/\/doi.org\/10.1016\/j.imlet.2017.11.012.","journal-title":"Immunol Lett"},{"issue":"5","key":"9329_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"No author list","year":"1980","unstructured":"No author list. Preliminary criteria for the classification of systemic sclerosis (scleroderma) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581\u201390.","journal-title":"Arthritis Rheum"},{"key":"9329_CR11","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"J Peterson","year":"2011","unstructured":"Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011."},{"key":"9329_CR12","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses (2022):. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 18 May 2022."},{"key":"9329_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.","journal-title":"BMC Med Res Methodol"},{"key":"9329_CR14","doi-asserted-by":"publisher","first-page":"825567","DOI":"10.3389\/fmed.2022.825567","volume":"9","author":"AG Versace","year":"2022","unstructured":"Versace AG, Bitto A, Ioppolo C, Aragona CO, La Rosa D, Roberts WN. IL-13 and IL-33 serum levels are increased in systemic sclerosis patients with interstitial lung disease. Front Med (Lausanne). 2022;9:825567. https:\/\/doi.org\/10.3389\/fmed.2022.825567.","journal-title":"Front Med (Lausanne)"},{"key":"9329_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cca.2019.06.026","volume":"496","author":"X Zhang","year":"2019","unstructured":"Zhang X, Yuan Y, Pan Z, Ma Y, Wu M, Yang J. Elevated circulating IL-17 level is associated with inflammatory arthritis and disease activity: a meta-analysis. Clin Chim Acta. 2019;496:76\u201383. https:\/\/doi.org\/10.1016\/j.cca.2019.06.026.","journal-title":"Clin Chim Acta"},{"issue":"11","key":"9329_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7414","key":"9329_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"7109","key":"9329_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"10","key":"9329_CR19","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1136\/ard.2010.148247","volume":"70","author":"M Manetti","year":"2011","unstructured":"Manetti M, Guiducci S, Ceccarelli C, Romano E, Bellando-Randone S, Conforti ML. Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis. 2011;70(10):1876\u20138. https:\/\/doi.org\/10.1136\/ard.2010.148247.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"9329_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1136\/ard.2009.119321","volume":"69","author":"M Manetti","year":"2010","unstructured":"Manetti M, Ibba-Manneschi L, Liakouli V, Guiducci S, Milia AF, Benelli G. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis. 2010;69(3):598\u2013605. https:\/\/doi.org\/10.1136\/ard.2009.119321.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9329_CR21","first-page":"5","volume":"17","author":"MA Mart\u00ednez-God\u00ednez","year":"2015","unstructured":"Mart\u00ednez-God\u00ednez MA, Cruz-Dom\u00ednguez MP, Jara LJ, Dom\u00ednguez-L\u00f3pez A, Jarillo-Luna RA, Vera-Lastra O. Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients. Isr Med Assoc J. 2015;17(1):5\u201310.","journal-title":"Isr Med Assoc J"},{"issue":"1","key":"9329_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/annrheumdis-2012-201553","volume":"72","author":"S Terras","year":"2013","unstructured":"Terras S, Opitz E, Moritz RK, H\u00f6xtermann S, Gambichler T, Kreuter A. Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis. Ann Rheum Dis. 2013;72(1):144\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201553.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"9329_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/sji.12317","volume":"82","author":"A Wagner","year":"2015","unstructured":"Wagner A, K\u00f6hm M, Nordin A, Svenungsson E, Pfeilschifter JM, Radeke HH. Increased serum levels of the IL-33 neutralizing sST2 in limited cutaneous systemic sclerosis. Scand J Immunol. 2015;82(3):269\u201374. https:\/\/doi.org\/10.1111\/sji.12317.","journal-title":"Scand J Immunol"},{"issue":"6","key":"9329_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10067-011-1686-5","volume":"30","author":"K Yanaba","year":"2011","unstructured":"Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol. 2011;30(6):825\u201330.","journal-title":"Clin Rheumatol"},{"key":"9329_CR25","doi-asserted-by":"publisher","unstructured":"Li D, Guabiraba R, Besnard A-G, Komai-Koma M, Jabir MS, Zhang L. IL-33 promotes ST2-dependent lung fibrosis by the induction\u00a0of alternatively activated macrophages and innate\u00a0lymphoid cells in mice. J Allergy Clin Immunol (2014): 134(6). https:\/\/doi.org\/10.1016\/j.jaci.2014.05.011.","DOI":"10.1016\/j.jaci.2014.05.011"},{"issue":"3","key":"9329_CR26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.4049\/jimmunol.0903306","volume":"184","author":"AL Rankin","year":"2010","unstructured":"Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol. 2010;184(3):1526\u201335. https:\/\/doi.org\/10.4049\/jimmunol.0903306.","journal-title":"J Immunol"},{"key":"9329_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbrep.2016.02.002","volume":"5","author":"H Hayakawa","year":"2016","unstructured":"Hayakawa H, Hayakawa M, Tominaga S-I. Soluble ST2 suppresses the effect of interleukin-33 on lung type 2 innate lymphoid cells. Biochem Biophys Rep. 2016;5:401\u20137. https:\/\/doi.org\/10.1016\/j.bbrep.2016.02.002.","journal-title":"Biochem Biophys Rep"},{"issue":"10","key":"9329_CR28","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.4049\/jimmunol.0901575","volume":"183","author":"M Kurowska-Stolarska","year":"2009","unstructured":"Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ. Ying S (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009;183(10):6469\u201377. https:\/\/doi.org\/10.4049\/jimmunol.0901575.","journal-title":"J Immunol"},{"key":"9329_CR29","doi-asserted-by":"publisher","unstructured":"MacDonald KG, Dawson NAJ, Huang Q, Dunne JV, Levings MK, Broady R. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J Allergy Clin Immunol (2015): 135(4). https:\/\/doi.org\/10.1016\/j.jaci.2014.12.1932.","DOI":"10.1016\/j.jaci.2014.12.1932"},{"issue":"3","key":"9329_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s10753-018-0742-6","volume":"41","author":"L Wu","year":"2018","unstructured":"Wu L, Luo Z, Zheng J, Yao P, Yuan Z, Lv X. IL-33 can promote the process of pulmonary fibrosis by inducing the imbalance between MMP-9 and TIMP-1. Inflammation. 2018;41(3):878\u201385. https:\/\/doi.org\/10.1007\/s10753-018-0742-6.","journal-title":"Inflammation"},{"issue":"6","key":"9329_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/00002281-200011000-00007","volume":"12","author":"FK Tan","year":"2000","unstructured":"Tan FK, Arnett FC. Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol. 2000;12(6):511\u20139.","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"9329_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00296-015-3417-8","volume":"36","author":"SS Koca","year":"2016","unstructured":"Koca SS, Pehlivan Y, Kara M, Alibaz-Oner F, Oztuzcu S, Yilmaz N. The IL-33 gene is related to increased susceptibility to systemic sclerosis. Rheumatol Int. 2016;36(4):579\u201384. https:\/\/doi.org\/10.1007\/s00296-015-3417-8.","journal-title":"Rheumatol Int"},{"issue":"4","key":"9329_CR33","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12026-016-8797-7","volume":"64","author":"XL Huang","year":"2016","unstructured":"Huang XL, Wu GC, Wang YJ, Yang XK, Yang GJ, Tao JH. Association of interleukin-1 family cytokines single nucleotide polymorphisms with susceptibility to systemic sclerosis: an independent case-control study and a meta-analysis. Immunol Res. 2016;64(4):1041\u201352. https:\/\/doi.org\/10.1007\/s12026-016-8797-7.","journal-title":"Immunol Res"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-022-09329-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T03:34:28Z","timestamp":1674012868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-022-09329-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["9329"],"URL":"https:\/\/doi.org\/10.1007\/s12026-022-09329-1","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}